IMGT/mAb-DB card

Version: 2.0.4 (2023-04-14)

Citing IMGT/mAb-DB

Manso T., Kushwaha A., Abdollahi N., Duroux P., Giudicelli V. and Kossida S. Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB. Front Immunol., 14 (2023). DOI 10.3389/fimmu.2023.1129323

Poiron C., Wu Y., Ginestoux C., Ehrenmann, Duroux P. and Lefranc M.-P. IMGT/mAb-DB: the IMGT® database for therapeutic monoclonal antibodies. JOBIM 2010, Paper 13 (2010). Abstract

Cambon M., Cherouali K., Kushwaha A., Giudicelli V., Duroux P., Kossida S. and Lefranc M.-P. IMGT/mAb-DB and IMGT/2Dstructure-DB for IMGT standard definition of an antibody: from receptor to amino acid changes. JOBIM 2018, Poster 201 (2018). Abstract

IMGT/mAb-DB ID	1248
INN	emfizatamab
INN Number	12023
INN Prop. List	126 (2022)
INN Rec. List	88 (2022)
Common name	GNC-038, GNC 038, GNC038
Proprietary name
Species	Homo sapiens Humanized
IMGT receptor type	IG
Format (legend)
Receptor identification	(scFv - kappa - heavy) - G1_L-kappa - (scFv - heavy - kappa) - (scFv - heavy - kappa)
Radiolabelled / Conjugated / Fused
IMGT/2Dstructure-DB	12023
IMGT/3Dstructure-DB
Specificity target name and species	CD19 (B lymphocyte surface antigen B4, Leu-12) [Homo sapiens, Humanized] CD3E (CD3e, CD3 epsilon) [Homo sapiens, Humanized] TNFRSF9 (tumor necrosis factor receptor (TNFR) superfamily member 9, 4-1BB, T cell antigen ILA, CD137) [Homo sapiens, Humanized] CD274 (programmed cell death 1 ligand 1, B7H1, B7-H1, PDL1, PD-L1, PDCD1L1, B7 homolog 1, B7 homologue 1) [Homo sapiens, Humanized] tetra-specific [Homo sapiens, Humanized]
Development Technology	Humanization by CDR grafting
Origin clone species	Oryctolagus cuniculus Homo sapiens
Origin clone name	; 9G8

Company	Sichuan Baili Pharmaceutical Co (Sichuan China)
Expression system
Application	Therapeutic
Clinical domain	Oncology
Mechanism of action
Clinical indication	Non-Hodgkin's lymphoma (NHL)
Development status	Phase I
Regulatory agency status and year

Company	Sichuan Baili Pharmaceutical Co (Sichuan China)
Expression system	CHO (Chinese Hamster Ovary) cells
Application	Therapeutic
Clinical domain	Oncology
Mechanism of action
Clinical indication	Lymphoma, diffuse large B cell (DLBCL)
Development status	Phase I/II
Regulatory agency status and year

Clinical trials
Authority decisions
External links
Biosimilars

Format legend:

IMGT/mAb-DB query | IMGT/mAb-DB documentation